Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POP-Durva
NCT05215106Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2021
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in triple-negative breast cancer (TNBC), sponsored by Gustave Roussy. Primary endpoint: Pathological Complete Response Rate at Day 29. Started Dec 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05215106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215106.